NASDAQ:GRI GRI Bio Q2 2026 Earnings Results & Report $1.77 -0.05 (-2.69%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more. GRI Bio beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.91 versus the -$1.19 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeBefore Market OpensConference Call7:00 AM ET GRI Bio EPS ResultsActual EPS-$0.91Consensus EPS -$1.19Beat/MissBeat by +$0.28One Year Ago EPSN/AEPS Beat Rate1 of last 4 quartersGRI Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsGRI Bio's Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) GRI Bio Q2 2026 Earnings FAQ Did GRI Bio beat earnings estimates for Q2 2026? GRI Bio (NASDAQ:GRI) reported earnings of -$0.91 per share for Q2 2026, beating the consensus estimate of -$1.19. The report was announced on Friday, August 14, 2026. When is GRI Bio's next earnings date? GRI Bio's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for GRI Bio on the company's earnings history page. GRI Bio Earnings HeadlinesGRI Bio (GRI) Projected to Release Earnings on FridayNovember 6, 2026 | americanbankingnews.comGRI Bio Stockholders Approve Directors and Equity Plan AmendmentNovember 4, 2026 | tipranks.comTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.November 13 at 1:00 AM | USA Capital Gold (Ad)Gri Bio, Inc. Highlights Immune Modulation and Phase 2A Development Insights in IPF At the 10Th IPF SummitSeptember 30, 2026 | marketscreener.comMGRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF SummitSeptember 28, 2026 | globenewswire.comUPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To BuySeptember 14, 2026 | benzinga.comSee More GRI Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email. Email Address About GRI BioGRI Bio (NASDAQ:GRI) (NASDAQ: GRI) is a clinical-stage biotechnology company focused on developing therapies that modulate natural killer T (NKT) cells. NKT cells are immune cells involved in regulating inflammation and immune responses, and the company is researching their potential role in autoimmune, inflammatory, and fibrotic diseases. GRI Bio’s lead product candidate is GRI-0621, an orally administered small-molecule inhibitor designed to selectively modulate type I NKT cells. The company has been evaluating GRI-0621 as a potential treatment for idiopathic pulmonary fibrosis, a progressive lung disease characterized by scarring and impaired respiratory function. GRI Bio is also advancing additional NKT-cell-focused compounds, including GRI-0633, for potential use in other immune-mediated conditions. The company’s development programs are based on research intended to identify how NKT-cell activity contributes to disease and whether targeted modulation can provide therapeutic benefits. GRI Bio is headquartered in the United States and is focused primarily on advancing its pipeline through clinical development and potential strategic partnerships. Information about the company’s current leadership and broader commercial operations is limited publicly.View GRI Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
